Mezigdomide Phase 3 Trial Shows 18-Month Median PFS, >50% Risk Reduction in Multiple Myeloma
BMY sits 34% above its 52-week low of $42.52 on elevated volume (2.4× avg).
Summary
Bristol Myers Squibb's oral drug mezigdomide in its Phase 3 SUCCESSOR-2 trial for relapsed/refractory multiple myeloma demonstrated an 18-month median progression-free survival (PFS) and over 50% reduction in the risk of progression or death. This news provides specific, strong clinical data following earlier announcements of positive Phase 3 results for mezigdomide in March and May. These detailed efficacy numbers solidify mezigdomide's profile as a significant potential oral later-line alternative to existing treatments like Revlimid and Pomalyst, impacting future revenue streams for the company. An FDA decision on iberdomide is expected in August.
At the time of this announcement, BMY was trading at $57.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $116.8B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.